

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 December 2021 (23.12.2021)



(10) International Publication Number
WO 2021/255479 A1

(51) International Patent Classification:
C12N 15/115 (2010.01) G01N 33/569 (2006.01)

(21) International Application Number:
PCT/GB2021/051559

(22) International Filing Date:
18 June 2021 (18.06.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2009351.4 18 June 2020 (18.06.2020) GB
2017437.1 04 November 2020 (04.11.2020) GB
2105379.8 15 April 2021 (15.04.2021) GB

(71) Applicant: **APTAMER DIAGNOSTICS LIMITED**
[GB/GB]; Suite 2.78 - 2.91 Bio Centre, Innovation Way,
Heslington, York North Yorkshire YO10 5NY (GB).

(72) Inventors: **TOLLEY, Arron**; c/o APTAMER DIAG-
NOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre, In-
novation Way, Heslington, York North Yorkshire YO10
5NY (GB). **BUNKA, David**; c/o APTAMER DIAG-
NOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre, In-
novation Way, Heslington, York North Yorkshire YO10
5NY (GB). **BARNES, Edward**; c/o APTAMER DIAG-
NOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre, In-
novation Way, Heslington, York North Yorkshire YO10
5NY (GB). **BALANSETHUPATHY, Banushan**; c/o AP-
TAMER DIAGNOSTICS LIMITED, Suite 2.78 - 2.91 Bio
Centre, Innovation Way, Heslington, York North York-
shire YO10 5NY (GB). **FLYNN, Harriet**; c/o APTAMER
DIAGNOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre,
Innovation Way, Heslington, York North Yorkshire YO10
5NY (GB). **ROBOTTOM, Janice**; c/o APTAMER DIAG-
NOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre, In-
novation Way, Heslington, York North Yorkshire YO10
5NY (GB). **MILBURN, Laura**; c/o APTAMER DIAG-
NOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre, In-
novation Way, Heslington, York North Yorkshire YO10
5NY (GB). **O'HARA, Phoebe**; c/o APTAMER DIAG-
NOSTICS LIMITED, Suite 2.78 - 2.91 Bio Centre, In-
novation Way, Heslington, York North Yorkshire YO10
5NY (GB). **REED, Joe**; c/o APTAMER DIAGNOSTICS
LIMITED, Suite 2.78 - 2.91 Bio Centre, Innovation Way,
Heslington, York North Yorkshire YO10 5NY (GB).

(74) Agent: **SECERNA LLP**; The Old Fire Station, 18 Clifford
Street, York North Yorkshire YO1 9RD (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: APTAMERS AGAINST SARS-COV-2

(57) Abstract: The invention relates to one or more aptamers isolated against the SARS-CoV-2 spike protein and methods of using the same. Certain embodiments of the invention relate to methods of detecting the presence, absence or amount of SARS-CoV-2 in a sample using the one or more aptamers described herein. In certain embodiments, the invention relates to one or more aptamers that are capable of specifically binding to SARS-CoV-2 proteins, including aptamers that are capable of specifically binding to the S1 subunit (including the receptor binding domain (RBD)) and/or the S2 subunit within their native conformation as part of the SARS-CoV-2 spike protein in its trimeric form or as separate monomers.



WO 2021/255479 A1